Abstract：
OBJECTIVE: To evaluate the feasibility, efficiency, and safety of microwave ablation (MWA) for multifocal papillary thyroid microcarcinoma (PTMC).
METHODS: This was a retrospective study, and the data of patients who underwent MWA for multifocal PTMC from October 2016 to December 2021 were reviewed. After ablation, the changes in tumor size and volume, as well as the rates of technical success, tumor disappearance, disease progression, and complications, were assessed. According to the tumor location, the cases were further divided into a unilateral multifocal disease (UMD) subgroup and a bilateral multifocal disease (BMD) subgroup. Further analyses were carried out.
RESULTS: There was a total of 94 cases enrolled in the present study, which included 24 males and 70 females. The median age was 40 years (22-66 years); the median follow-up time was 14 months (6-48 months). Complete ablation was achieved in all enrolled cases. Therefore, the technical success rate was 100%. Due to expanding ablation, the MD and volume of the ablation zone increased at the 1st and 3rd months after ablation and decreased from the 12th month after ablation (p < 0.05 for all). The total complete tumor disappearance rates were 45/94 (47.87%) overall, 40.625% (13/32) in the UMD subgroup and 51.61% (32/62) in the BMD subgroup (p = 0.312). The total disease progression rates were 4.26% (4/94) overall, 6.25% (2/32) in the UMD subgroup and 3.23% (2/62) in the BMD subgroup (p = 0.881). The overall complication rate was 4.26% (4/94).
CONCLUSIONS: This preliminary study indicates that MWA is a safe and effective treatment for multifocal PTMC.
METHODS: This was a retrospective study, and the data of patients who underwent MWA for multifocal PTMC from October 2016 to December 2021 were reviewed. After ablation, the changes in tumor size and volume, as well as the rates of technical success, tumor disappearance, disease progression, and complications, were assessed. According to the tumor location, the cases were further divided into a unilateral multifocal disease (UMD) subgroup and a bilateral multifocal disease (BMD) subgroup. Further analyses were carried out.
RESULTS: There was a total of 94 cases enrolled in the present study, which included 24 males and 70 females. The median age was 40 years (22-66 years); the median follow-up time was 14 months (6-48 months). Complete ablation was achieved in all enrolled cases. Therefore, the technical success rate was 100%. Due to expanding ablation, the MD and volume of the ablation zone increased at the 1st and 3rd months after ablation and decreased from the 12th month after ablation (p < 0.05 for all). The total complete tumor disappearance rates were 45/94 (47.87%) overall, 40.625% (13/32) in the UMD subgroup and 51.61% (32/62) in the BMD subgroup (p = 0.312). The total disease progression rates were 4.26% (4/94) overall, 6.25% (2/32) in the UMD subgroup and 3.23% (2/62) in the BMD subgroup (p = 0.881). The overall complication rate was 4.26% (4/94).
CONCLUSIONS: This preliminary study indicates that MWA is a safe and effective treatment for multifocal PTMC.
摘要：
目的：为了评估可行性，效率,微波消融（MWA）治疗多灶性甲状腺乳头状微小癌（PTMC）的安全性。
方法：这是一项回顾性研究，我们回顾了2016年10月至2021年12月期间接受MWA治疗多灶性PTMC的患者数据.消融后,肿瘤大小和体积的变化，以及技术成功率，肿瘤消失,疾病进展,和并发症，被评估。根据肿瘤的位置,将病例进一步分为单侧多灶性疾病(UMD)亚组和双侧多灶性疾病(BMD)亚组.进行了进一步的分析。
结果：本研究共纳入94例，其中包括24名男性和70名女性。中位年龄为40岁（22-66岁）；中位随访时间为14个月（6-48个月）。所有登记病例均实现了完全消融。因此,技术成功率为100%。由于消融扩大,消融区的MD和体积在消融术后的第1个月和第3个月增加，从消融术后的第12个月减少（全部p<0.05）。肿瘤完全消失率为45/94(47.87%),UMD亚组40.625%(13/32),BMD亚组51.61%(32/62)(p=0.312)。总体疾病进展率为4.26%(4/94),UMD亚组6.25%(2/32),BMD亚组3.23%(2/62)(p=0.881)。总并发症发生率为4.26%(4/94)。
结论：这项初步研究表明，MWA是多灶性PTMC的安全有效治疗方法。
方法：这是一项回顾性研究，我们回顾了2016年10月至2021年12月期间接受MWA治疗多灶性PTMC的患者数据.消融后,肿瘤大小和体积的变化，以及技术成功率，肿瘤消失,疾病进展,和并发症，被评估。根据肿瘤的位置,将病例进一步分为单侧多灶性疾病(UMD)亚组和双侧多灶性疾病(BMD)亚组.进行了进一步的分析。
结果：本研究共纳入94例，其中包括24名男性和70名女性。中位年龄为40岁（22-66岁）；中位随访时间为14个月（6-48个月）。所有登记病例均实现了完全消融。因此,技术成功率为100%。由于消融扩大,消融区的MD和体积在消融术后的第1个月和第3个月增加，从消融术后的第12个月减少（全部p<0.05）。肿瘤完全消失率为45/94(47.87%),UMD亚组40.625%(13/32),BMD亚组51.61%(32/62)(p=0.312)。总体疾病进展率为4.26%(4/94),UMD亚组6.25%(2/32),BMD亚组3.23%(2/62)(p=0.881)。总并发症发生率为4.26%(4/94)。
结论：这项初步研究表明，MWA是多灶性PTMC的安全有效治疗方法。
